Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China · Delayed Price · Currency is CNY 12.46
+0.47 (3.92%)
Jul 25, 2025, 3:00 PM CST
SHA:603567 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 2,029 | 2,677 | 3,084 | 4,199 | 4,120 | 3,390 | Upgrade |
Other Revenue | 26.93 | 26.93 | 54.11 | 14.68 | 6.5 | 14.22 | Upgrade |
| 2,056 | 2,704 | 3,138 | 4,214 | 4,127 | 3,404 | Upgrade | |
Revenue Growth (YoY) | -31.29% | -13.84% | -25.53% | 2.12% | 21.24% | 3.40% | Upgrade |
Cost of Revenue | 990.19 | 1,334 | 1,846 | 3,539 | 2,829 | 1,515 | Upgrade |
Gross Profit | 1,065 | 1,370 | 1,292 | 675.25 | 1,298 | 1,888 | Upgrade |
Selling, General & Admin | 520.22 | 575.22 | 979.01 | 915.17 | 952.16 | 1,054 | Upgrade |
Research & Development | 37.37 | 37.99 | 80.22 | 70.95 | 55.23 | 81.34 | Upgrade |
Other Operating Expenses | 41.25 | 36.03 | 43.79 | -64.36 | -24.14 | 132.34 | Upgrade |
Operating Expenses | 749.79 | 767.06 | 1,107 | 891.96 | 1,028 | 1,303 | Upgrade |
Operating Income | 315.6 | 602.9 | 185.52 | -216.71 | 270.38 | 585.35 | Upgrade |
Interest Expense | -135.41 | -137.09 | -135.41 | -138.68 | -144.79 | -149.61 | Upgrade |
Interest & Investment Income | 13.4 | 22.69 | 471.68 | 38.06 | 251.32 | 31.87 | Upgrade |
Currency Exchange Gain (Loss) | - | - | - | -0 | -0 | -0 | Upgrade |
Other Non Operating Income (Expenses) | 6.22 | 9.22 | -88.59 | 26.83 | -22.32 | -1.85 | Upgrade |
EBT Excluding Unusual Items | 198.67 | 497.73 | 433.2 | -290.5 | 354.6 | 465.76 | Upgrade |
Impairment of Goodwill | - | - | -2.4 | -1.28 | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -9.82 | -9.69 | 0.6 | -1.75 | -0.15 | -16.98 | Upgrade |
Gain (Loss) on Sale of Assets | -1.83 | -1.68 | -0.26 | 39.33 | -1.11 | -0.21 | Upgrade |
Asset Writedown | 18.2 | -0.63 | -1.51 | - | -0.09 | - | Upgrade |
Other Unusual Items | 40.75 | 37.75 | 48.72 | 552.68 | 101.49 | 88.68 | Upgrade |
Pretax Income | 245.98 | 523.47 | 478.35 | 298.48 | 454.75 | 537.25 | Upgrade |
Income Tax Expense | 28.84 | 87.08 | 10.76 | 107.55 | 121.99 | 99.75 | Upgrade |
Earnings From Continuing Operations | 217.14 | 436.39 | 467.59 | 190.93 | 332.76 | 437.5 | Upgrade |
Minority Interest in Earnings | 3.01 | 1.82 | 5.15 | -5.49 | -0.66 | -1.22 | Upgrade |
Net Income | 220.15 | 438.22 | 472.74 | 185.44 | 332.1 | 436.29 | Upgrade |
Net Income to Common | 220.15 | 438.22 | 472.74 | 185.44 | 332.1 | 436.29 | Upgrade |
Net Income Growth | -58.43% | -7.30% | 154.93% | -44.16% | -23.88% | 6.76% | Upgrade |
Shares Outstanding (Basic) | 940 | 940 | 939 | 941 | 865 | 849 | Upgrade |
Shares Outstanding (Diluted) | 940 | 940 | 940 | 941 | 865 | 849 | Upgrade |
Shares Change (YoY) | 0.11% | -0.01% | -0.14% | 8.87% | 1.82% | -0.01% | Upgrade |
EPS (Basic) | 0.23 | 0.47 | 0.50 | 0.20 | 0.38 | 0.51 | Upgrade |
EPS (Diluted) | 0.23 | 0.47 | 0.50 | 0.20 | 0.38 | 0.51 | Upgrade |
EPS Growth | -58.47% | -7.30% | 155.28% | -48.71% | -25.24% | 6.78% | Upgrade |
Free Cash Flow | -210.23 | -24.84 | -573.38 | -731.07 | -882.57 | -713.47 | Upgrade |
Free Cash Flow Per Share | -0.22 | -0.03 | -0.61 | -0.78 | -1.02 | -0.84 | Upgrade |
Dividend Per Share | 0.150 | 0.150 | 0.200 | 0.028 | 0.106 | - | Upgrade |
Dividend Growth | -25.00% | -25.00% | 614.29% | -73.58% | - | - | Upgrade |
Gross Margin | 51.83% | 50.67% | 41.18% | 16.02% | 31.45% | 55.48% | Upgrade |
Operating Margin | 15.35% | 22.30% | 5.91% | -5.14% | 6.55% | 17.20% | Upgrade |
Profit Margin | 10.71% | 16.21% | 15.06% | 4.40% | 8.05% | 12.82% | Upgrade |
Free Cash Flow Margin | -10.23% | -0.92% | -18.27% | -17.35% | -21.39% | -20.96% | Upgrade |
EBITDA | 463.45 | 756.94 | 364.32 | -59.75 | 405.93 | 741.23 | Upgrade |
EBITDA Margin | 22.55% | 27.99% | 11.61% | -1.42% | 9.84% | 21.78% | Upgrade |
D&A For EBITDA | 147.85 | 154.04 | 178.8 | 156.95 | 135.55 | 155.89 | Upgrade |
EBIT | 315.6 | 602.9 | 185.52 | -216.71 | 270.38 | 585.35 | Upgrade |
EBIT Margin | 15.35% | 22.30% | 5.91% | -5.14% | 6.55% | 17.20% | Upgrade |
Effective Tax Rate | 11.73% | 16.63% | 2.25% | 36.03% | 26.82% | 18.57% | Upgrade |
Revenue as Reported | 2,058 | 2,707 | 3,144 | 4,219 | 4,130 | 3,411 | Upgrade |
Advertising Expenses | - | 15.94 | 10.42 | 3.57 | 2.17 | 3.74 | Upgrade |
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.